Holen Sie sich die Stockscreener-App
3.25
2.52%
0.08
Schlusskurs vom Vortag:
$3.17
Offen:
$3.17
24-Stunden-Volumen:
62,934
Relative Volume:
0.26
Marktkapitalisierung:
$129.36M
Einnahmen:
$2.70M
Nettoeinkommen (Verlust:
$5.53M
KGV:
29.55
EPS:
0.11
Netto-Cashflow:
$-10.55M
1W Leistung:
-4.69%
1M Leistung:
-4.13%
6M Leistung:
+53.30%
1J Leistung:
+32.65%
1-Tages-Spanne:
$3.15
$3.325
1-Wochen-Bereich:
$3.14
$3.51
52-Wochen-Spanne:
$1.82
$3.71
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
3.25 | 126.17M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Up 57.8% in January - MarketBeat
Geopolitics Watch: Can Oramed Pharmaceuticals Inc keep up with sector leaders2025 Earnings Surprises & Weekly Top Gainers Trade List - baoquankhu1.vn
What are analysts’ price targets for Oramed Pharmaceuticals Inc.2025 Analyst Calls & Free Daily Entry Point Trade Alerts - mfd.ru
Support Test: Should you avoid Oramed Pharmaceuticals Inc stock right now2025 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Will Oramed Pharmaceuticals Inc. (OJU1) stock test record highs in 2025Weekly Earnings Recap & Reliable Momentum Entry Alerts - mfd.ru
Can Oramed Pharmaceuticals Inc. maintain sales growthJuly 2025 Levels & Real-Time Stock Price Movement Reports - mfd.ru
What drives Oramed Pharmaceuticals Inc.’s stock priceDividend Hike & Accurate Trade Setup Notifications - mfd.ru
What hedge funds are buying Oramed Pharmaceuticals Inc.2025 Winners & Losers & Verified Momentum Stock Alerts - mfd.ru
Aug Outlook: How much upside does Bakkt Holdings Inc Equity Warrant haveRecession Risk & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bull Bear: What is the target price for Oramed Pharmaceuticals Inc. stockSwing Trade & Intraday High Probability Alerts - mfd.ru
NNDM stock in focus: Nano Dimension pops a poison pill days after Oramed stake build-up - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) & Demant A/S (OTCMKTS:WILYY) Head to Head Analysis - Defense World
Pullback Watch: Is Oramed Pharmaceuticals Inc stock a smart retirement pickQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
What is the next catalyst for Oramed Pharmaceuticals Inc.July 2025 Sentiment & Stock Portfolio Risk Control - mfd.ru
Swing Trade: What is Oramed Pharmaceuticals Incs 5 year growth outlookJuly 2025 Market Mood & Breakout Confirmation Trade Signals - baoquankhu1.vn
Oramed Pharmaceuticals Achieves 60.85% Return, Leading Market Performance - Markets Mojo
OraTech to pioneer oral insulin with $75 million investment - MSN
Oramed Pharm completes warrant sale, boosting liquidity - MSN
NNDM Stock In Focus: Nano Dimension Pops A Poison Pill Days After Oramed Stake Build-Up - Stocktwits
Aug Update: What is ReTo Eco Solutions Incs book value per shareJuly 2025 Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Is Oramed Pharmaceuticals Inc. stock a smart retirement pickJuly 2025 Short Interest & Trade Opportunity Analysis Reports - mfd.ru
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Jobs Data: Is Oramed Pharmaceuticals Inc stock good for income investors2025 Historical Comparison & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Oramed Shares Face Pressure Amid Strategic Pivot and Dividend Focus - AD HOC NEWS
Is Oramed Pharmaceuticals Inc. stock undervalued right nowVolume Analysis Techniques & Plan Every Trade With Controlled Risk - bollywoodhelpline.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Large Increase in Short Interest - MarketBeat
Published on: 2026-01-17 10:34:33 - baoquankhu1.vn
Oramed Pharmaceuticals Inc.: - marketscreener.com
Oramed Pharm pivots with Lifeward strategic platform deal - TipRanks
Oramed Pharmaceuticals Signs Multiple Material Agreements - TradingView — Track All Markets
3 Promising Penny Stocks With Market Caps Under $200M - simplywall.st
Oramed to transfer oral drug delivery platform to Lifeward By Investing.com - Investing.com Nigeria
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal - Investing.com Nigeria
Lifeward Forms Strategic Partnership and Financing Deal with Oramed - The Globe and Mail
Buyout Rumor: Can Oramed Pharmaceuticals Inc maintain sales growthQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Oramed And Lifeward Reveal Strategic Deal - Pulse 2.0
Oramed to transfer oral drug delivery platform to Lifeward - Investing.com India
Lifeward to acquire Oramed’s oral protein delivery tech in $47 million deal By Investing.com - Investing.com South Africa
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - manilatimes.net
Oramed and Lifeward Announce Strategic Transaction - Financial Times
Lifeward Ltd. announced that it expects to receive $20 million in funding from Oramed Pharmaceuticals Inc. - marketscreener.com
Oramed Announces Shareholder Capital Return Following Strategic Windfall - AD HOC NEWS
Take Profit: Will Oramed Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Intraday Action & Growth Focused Investment Plans - Улправда
Why Oramed Pharmaceuticals Inc. stock could outperform in 2025Trade Performance Summary & Risk Managed Investment Entry Signals - Улправда
Is Oramed Pharmaceuticals Inc. stock a buy in volatile markets2025 Retail Activity & Daily Volume Surge Signals - ulpravda.ru
Will Oramed Pharmaceuticals Inc. stock outperform value stocks2025 Key Lessons & Intraday High Probability Alerts - ulpravda.ru
Oramed Pharmaceuticals Inc. Declares Dividend of $0.25 (NASDAQ:ORMP) - MarketBeat
Oramed inks deal with Medicox for oral insulin in South Korea - The Pharma Letter
Is Oramed Pharmaceuticals Inc. (OJU1) stock suitable for passive index fundsMarket Sentiment Shifts & Outstanding Capital Returns - Улправда
MSN Money - MSN
Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026 - MarketScreener
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oramed Pharmaceuticals Inc-Aktie (ORMP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kidron Miriam | Chief Scientific Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
1,448,664 |
| Gabay Avraham | Chief Financial Officer |
Jan 22 '26 |
Option Exercise |
0.00 |
19,000 |
0 |
649,256 |
| KIDRON NADAV | President and CEO |
Jan 22 '26 |
Option Exercise |
0.00 |
109,000 |
0 |
3,355,238 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):